Review of evolving treatment approaches in pediatric patients with newly diagnosed AML
To continue, select another chapter from the Chapter List
Release Date: April 29, 2022
Expiration Date: April 29, 2023
Expected time to complete this activity as designed: 15 minutes
There are no fees for participating in or receiving credit for this online activity.
Acute myeloid leukemia (AML) is the second most common blood cancer in children. In current care, clinicians are working to identify specific molecular subtypes in AML. In this activity, Dr. Aplenc explains how we might tailor therapies to these subtypes and how new therapies may improve outcomes.
This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, nurse practitioners, pharmacists and other allied healthcare professionals who provide care to patients with acute myeloid leukemia.
Upon completion of this educational activity, participants should be able to:
- Summarize efficacy and safety data associated with new advances in the treatment and management of pediatric patients with AML
- Outline considerations for applying new therapeutic advances to the treatment of pediatric patients with AML
Review of evolving treatment approaches in pediatric patients with newly diagnosed AML – Richard Aplenc, MD, PhD, MSCE
Instructions for Participation and Credit
This activity is eligible for credit through April 29, 2023. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Richard Aplenc, MD, PhD, MSCE
Professor of Pediatrics
Children's Hospital of Philadelphia
University of Pennsylvania School of Medicine
Dr. Richard Aplenc received his medical degree from the University of Virginia School of Medicine. He completed his internship and residency in pediatrics at the University of California at San Diego and his fellowship in pediatric hematology/oncology at Children's Hospital of Philadelphia (CHOP), University of Pennsylvania School of Medicine. In addition, he received a PhD in epidemiology from the University of Pennsylvania. Dr. Aplenc is a Professor of Pediatrics in the Department of Pediatrics and a core faculty member of the Center for Pediatric Clinical Effectiveness at CHOP. He holds the Mai and Harry F. West Endowed Chair in Pediatric Research. In addition, he is Professor of Epidemiology in Biostatistics and Epidemiology at the University of Pennsylvania School of Medicine.
Dr Aplenc is American Board of Pediatrics certified in hematology-oncology. He is Chief Clinical Research Officer at CHOP, and is an editorial reviewer for numerous peer-reviewed journals. Dr. Aplenc’s research focuses on improving the outcomes of children with cancer, particularly acute myeloid leukemia (AML). His work involves the treatment of AML in children and the use of genetic data to predict treatment response to therapeutic interventions.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at [email protected]
Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Jazz Pharmaceuticals.
©2022 MediCom Worldwide, Inc., 660 Newtown Yardley Rd, Suite 203 • Newtown, PA 18940, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.25 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-22-004-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
|Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.|
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an accredited continuing education activity to disclose all financial relationships with any ineligible company. The ACCME defines “ineligible companies” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products by or on patients. A relevant relationship exists if a financial relationship in any amount exists between the person in control of content and an ineligible company; the financial relationship existed during the past 24 months and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. MediCom will identify mitigation strategies for all persons with relevant financial relationships who control content of the educational activity.
Dr. Richard Aplenc, faculty for this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses of products or devices.
Joan Meyer, RN, MHA, Executive Director, Isabelle Vacher, Vice President of Educational Strategy, Andrew Bowser, Medical Writer, and Andrea Mathis, Project Manager, planners for this educational activity, have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
Peer reviewer(s) for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.